Quest study shows Haystack MRD test hits 100% specificity in DYNAMIC colorectal cancer specimen cohort

By Public Technologies
  • Quest Diagnostics highlighted a new Journal of Molecular Diagnostics study validating its Haystack MRD blood test in colorectal cancer.
  • Results have already been published, based on retrospective testing of stored samples from the DYNAMIC and DYNAMIC-III clinical trial programs.
  • The study found the test accurately identified patients likely to relapse, with no false alarms reported in the evaluated cohort.
  • Haystack MRD outperformed a commonly used blood biomarker for spotting recurrence, supporting broader clinical adoption and potential treatment-monitoring use.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quest Diagnostics Incorporated published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610010852PR_NEWS_USPR_____NY61005) on October 01, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk